Phase III
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 6, 2020.
One of the promising experimental drugs being tested to treat COVID-19, the disease caused by the novel coronavirus SARS-Cov2-, is Gilead Sciences’ remdesivir.
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
Novartis announced that, with Incyte, it is launching a Phase III clinical trial to determine if their cancer drug Jakavi (ruxolitinib) can be used to treat COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
A late-stage lung cancer drug under development by OSE Immunotherapeutics met its 12-month primary endpoint for survival rates following a Step-1 analysis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
Keytruda (pembrolizumab) hit one of the coprimary endpoints early in the Phase III KEYNOTE-177 clinical trial for a highly mutating form of colorectal cancer.
The companies initiated a Phase II/III trial in Italy, Spain, Germany, France, Japan, Canada and Russia.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 1, 2020.
PRESS RELEASES